Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Celgene maintains growth trajectory in second quarter

Celgene maintains growth trajectory in second quarter

29th July 2011

Celgene has reported another quarter of strong business growth in the three months ending on June 30th 2011.

Non-GAAP total revenue reached a record total of $1.1 billion (676 million pounds) during the second quarter, up by 38 percent year on year, with the majority of this total generated by Revlimid.

The oncology therapy, alongside Vidaza, saw a double-digit sales increase during this period, while numerous clinical studies were conducted to show its efficacy in specifications such as multiple myeloma and follicular lymphoma.

As a result of the progress made, Celgene has increased its forecasts for the full-year period and now expects a revenue increase of around 29 percent, placing the total within the $4.6 billion to $4.7 billion range.

"The quarterly results were outstanding and reflect the therapeutic value of our novel therapies for patients worldwide," said Bob Hugin, chief executive officer of Celgene.

Last month, the company's Thalidomide treatment was recommended in final draft guidance from the UK's National Institute for Health and Clinical Excellence as a multiple myeloma therapy.ADNFCR-8000103-ID-800638620-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.